The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
出版年份 2021 全文链接
标题
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
作者
关键词
-
出版物
DRUGS
Volume 81, Issue 15, Pages 1703-1729
出版商
Springer Science and Business Media LLC
发表日期
2021-10-11
DOI
10.1007/s40265-021-01611-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China
- (2021) Huilin Su et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology
- (2021) Martin Hoenigl et al. LANCET INFECTIOUS DISEASES
- Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
- (2021) Ahmed Gamal et al. Frontiers in Cellular and Infection Microbiology
- Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes
- (2021) Hamid Badali et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of Talaromyces marneffei
- (2021) Jing Zhang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes
- (2021) Hamid Badali et al. MYCOSES
- A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women
- (2021) Amir Arastehfar et al. Frontiers in Microbiology
- In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies
- (2021) Olga Rivero-Menendez et al. Journal of Fungi
- Environmental Clonal Spread of Azole-Resistant Candida parapsilosis with Erg11-Y132F Mutation Causing a Large Candidemia Outbreak in a Brazilian Cancer Referral Center
- (2021) Danilo Y. Thomaz et al. Journal of Fungi
- In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents
- (2021) Ourania Georgacopoulos et al. Journal of Fungi
- Multidrug-resistant Trichosporon species: underestimated fungal pathogens posing imminent threats in clinical settings
- (2021) Amir Arastehfar et al. CRITICAL REVIEWS IN MICROBIOLOGY
- Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry
- (2021) Juergen Prattes et al. INTENSIVE CARE MEDICINE
- COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges
- (2021) Juergen Prattes et al. INTENSIVE CARE MEDICINE
- ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countries
- (2021) Shivaprakash M. Rudramurthy et al. MYCOSES
- Aspergillus fumigatus and aspergillosis: From basics to clinics
- (2021) A. Arastehfar et al. STUDIES IN MYCOLOGY
- Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)
- (2021) Michael A. Pfaller et al. Journal of Global Antimicrobial Resistance
- Investigational Agents for the Treatment of Resistant Yeasts and Molds
- (2021) Garret T. Seiler et al. Current Fungal Infection Reports
- Rezafungin In Vitro Activity against Contemporary Clinical Nordic Candida Isolates and Candida auris Determined by the EUCAST Reference Method
- (2020) Marie Helleberg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008–2019
- (2020) J.D. Jenks et al. CLINICAL MICROBIOLOGY AND INFECTION
- Pan-resistant Candida auris Isolates from the Outbreak in New York are Susceptible to Ibrexafungerp: A Glucan Synthase Inhibitor
- (2020) Yan Chun Zhu et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical Characteristics and Outcomes of invasive Lomentospora prolificans Infections: Analysis of Patients in the FungiScope® Registry
- (2020) Jeffrey D. Jenks et al. MYCOSES
- Drug resistance and tolerance in fungi
- (2020) Judith Berman et al. NATURE REVIEWS MICROBIOLOGY
- Hope on the Horizon: Novel Fungal Treatments in Development
- (2020) Adriana M Rauseo et al. Open Forum Infectious Diseases
- Manogepix (APX001A) displays potent in vitro activity against human pathogenic yeast, but with an unexpected correlation to fluconazole MICs
- (2020) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-D-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
- (2020) Vidmantas Petraitis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
- (2020) Teclegiorgis Gebremariam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure
- (2020) Amir Arastehfar et al. MYCOSES
- Mutations in TAC1B: a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
- (2020) Jeffrey M. Rybak et al. mBio
- In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination
- (2020) Karin Meinike Jørgensen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Manogepix (APX001A) in vitro activity against Candida auris. A head to head comparison of EUCAST and CLSI MICs.
- (2020) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- First report of candidemia clonal outbreak caused by emerging fluconazole-resistant Candida parapsilosis isolates harboring Y132F and/or Y132F+K143R in Turkey
- (2020) Amir Arastehfar et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus
- (2020) Lisa Kirchhoff et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope® — Global Registry for Emerging Fungal Infections
- (2020) Jon SALMANTON-GARCÍA et al. JOURNAL OF INFECTION
- Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
- (2020) Robert T Todd et al. eLife
- Review of the Novel Investigational Antifungal Olorofim
- (2020) Nathan P. Wiederhold Journal of Fungi
- COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment
- (2020) Amir Arastehfar et al. Journal of Fungi
- Olorofim susceptibility testing of 1423 Danish mould isolates 2018-2019 confirms uniform and broad-spectrum activity.
- (2020) Karen Marie Thyssen Astvad et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak
- (2020) YanChun Zhu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial
- (2020) George R Thompson et al. CLINICAL INFECTIOUS DISEASES
- Invasive Fungal Disease Complicating Coronavirus Disease 2019: When It Rains, It Spores
- (2020) Martin Hoenigl CLINICAL INFECTIOUS DISEASES
- In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies
- (2020) Olga Rivero-Menendez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Recent Increase in the Prevalence of Fluconazole-Non-susceptible Candida tropicalis Blood Isolates in Turkey: Clinical Implication of Azole-Non-susceptible and Fluconazole Tolerant Phenotypes and Genotyping
- (2020) Amir Arastehfar et al. Frontiers in Microbiology
- Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement
- (2020) Jeffrey D. Jenks et al. Journal of Fungi
- The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
- (2020) Amir Arastehfar et al. Journal of Fungi
- Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
- (2020) Karen Joy Shaw et al. Journal of Fungi
- Oral ibrexafungerp efficacy and safety in the treatment of vulvovaginal candidiasis: A phase 3, randomized, blinded, study vs. placebo (VANISH-303)
- (2020) J.R. Schwebke et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
- (2020) Lynn Miesel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species
- (2020) Ashutosh Singh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
- (2020) Philipp Koehler et al. LANCET INFECTIOUS DISEASES
- Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
- (2020) Amir Arastehfar et al. Antibiotics-Basel
- Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent
- (2020) Lindsey Cass et al. Pharmacology Research & Perspectives
- AtrR Is an Essential Determinant of Azole Resistance in Aspergillus fumigatus
- (2019) Sanjoy Paul et al. mBio
- In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies
- (2019) Olga Rivero-Menendez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies
- (2019) Olga Rivero-Menendez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- No Relevant Pharmacokinetic (PK) Interaction between Rezafungin and Nine Probe Drugs: Results from a Drug-Drug Interaction (DDI) Study
- (2019) Voon Ong et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis
- (2019) Miao Zhao et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A novel 1,3-beta-D-glucan inhibitor, Ibrexafungerp (formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis.
- (2019) E. L. Larkin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Evolution of Azole Resistance in Candida albicans Sterol 14α-Demethylase (CYP51) through Incremental Amino Acid Substitutions
- (2019) Andrew G. Warrilow et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017
- (2019) M. A. Pfaller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis
- (2019) Andrej Spec et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ibrexafungerp: A novel oral glucan synthase inhibitor
- (2019) M R Davis et al. MEDICAL MYCOLOGY
- Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-D-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus
- (2019) Shruthi Satish et al. mBio
- Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection
- (2019) Thomas Colley et al. Scientific Reports
- Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
- (2019) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
- (2019) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations
- (2019) Natalie S. Nunnally et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against Candida glabrata
- (2019) M. Ghannoum et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
- (2019) Zoltán Tóth et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection
- (2019) Teklegiorgis Gebremariam et al. Open Forum Infectious Diseases
- A phase 2b, dose-selection study evaluating the efficacy and safety of oral ibrexafungerp vs fluconazole in vulvovaginal candidiasis (DOVE)
- (2019) D. Angulo et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
- (2019) Sondus Alkhazraji et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents
- (2019) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim
- (2019) Wilson Lim et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
- (2019) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates
- (2019) Amir Arastehfar et al. MEDICAL MYCOLOGY
- Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects
- (2019) Shawn Flanagan et al. Clinical Pharmacology in Drug Development
- Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy
- (2018) Ziauddin Khan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Orotomide Olorofim is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis
- (2018) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
- (2018) Milena Kordalewska et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
- (2018) Miao Zhao et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro and in vivo Evaluation of APX001A/APX001 and other Gwt1 inhibitors against Cryptococcus
- (2018) Karen Joy Shaw et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against echinocandin and multidrug resistant Candida isolates in a mouse model of invasive candidiasis
- (2018) Yanan Zhao et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
- (2018) Christopher L. Hager et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis
- (2018) M. Ghannoum et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method
- (2018) M.C. Arendrup et al. CLINICAL MICROBIOLOGY AND INFECTION
- Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species
- (2018) Nathan P Wiederhold et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance
- (2018) Anuradha Chowdhary et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol
- (2018) Alexander F. A. D. Schauwvlieghe et al. MYCOSES
- Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia
- (2018) Alexander Rosenberg et al. Nature Communications
- Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
- (2018) Jeffrey D Jenks et al. Drug Design Development and Therapy
- Contributions of yap1 mutation and subsequent atrF upregulation to voriconazole resistance in Aspergillus flavus
- (2018) Yuuta Ukai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- C. albicans Zn Cluster Transcription Factors Tac1 and Znc1 are Activated by Farnesol to Up Regulate a Transcriptional Program Including the Multi-Drug Efflux Pump CDR1
- (2018) Zhongle Liu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Reliable and easy-to-use Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) assay for quantification of Olorofim (F901318) – a novel antifungal drug – in human plasma and serum
- (2018) Carsten Müller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Implications of the “EUCAST trailing” phenomenon in C. tropicalis for the in vivo susceptibility in invertebrate and murine models.
- (2018) KMT Astvad et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method
- (2018) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rare Mold Infections Caused by Mucorales, Lomentospora Prolificans and Fusarium , San Diego: The Role of Antifungal Combination Therapy
- (2018) Jeffrey D. Jenks et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- SCY-078, a novel IV/oral triterpenoid anti-fungal treatment in development for vulvovaginal candidiasis and other severe invasive fungal infections, is not embryo/feto-toxic
- (2018) C. Carruthers et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- APX001 is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
- (2018) Teclegiorgis Gebremariam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- APX001 and Other Gwt1 inhibitor Prodrugs are Effective in Experimental Coccidioides immitis Pneumonia
- (2018) Suganya Viriyakosol et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- SCY-078, A Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections During Mass Balance Studies with IV and PO 14C-SCY-078 in Albino and Pigmented Rats
- (2018) Stephen Wring et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program
- (2017) Michael A. Pfaller et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates
- (2017) J. B. Buil et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.
- (2017) Laura Judith Marcos-Zambrano et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans
- (2017) Nathan P. Wiederhold et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern
- (2017) K. M. T. Astvad et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus
- (2017) Clara E Negri et al. JOURNAL OF INFECTIOUS DISEASES
- The global problem of antifungal resistance: prevalence, mechanisms, and management
- (2017) David S Perlin et al. LANCET INFECTIOUS DISEASES
- A Novel Zn2-Cys6 Transcription Factor AtrR Plays a Key Role in an Azole Resistance Mechanism of Aspergillus fumigatus by Co-regulating cyp51A and cdr1B Expressions
- (2017) Daisuke Hagiwara et al. PLoS Pathogens
- First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
- (2017) Michael R Hodges et al. Open Forum Infectious Diseases
- APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
- (2017) Teclegiorgis Gebremariam et al. Open Forum Infectious Diseases
- Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability
- (2017) Michael R Hodges et al. Open Forum Infectious Diseases
- Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
- (2016) Voon Ong et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization ofIn VitroResistance Development to the Novel Echinocandin CD101 in Candida Species
- (2016) Jeffrey B. Locke et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties
- (2016) Kenneth D. James et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Aspergillus fumigatus Intrinsic Fluconazole Resistance Is Due to the Naturally Occurring T301I Substitution in Cyp51Ap
- (2016) Florencia Leonardelli et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
- (2016) Taylor Sandison et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, againstCandidaandAspergillusspp., including echinocandin- and azole-resistant isolates
- (2016) Michael A. Pfaller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
- (2016) Johan A Maertens et al. LANCET
- F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
- (2016) Jason D. Oliver et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sterol Biosynthesis and Azole Tolerance Is Governed by the Opposing Actions of SrbA and the CCAAT Binding Complex
- (2016) Fabio Gsaller et al. PLoS Pathogens
- Upregulation of the Adhesin Gene EPA1 Mediated by PDR1 in Candida glabrata Leads to Enhanced Host Colonization
- (2016) Luis A. Vale-Silva et al. mSphere
- Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates
- (2015) Frédéric Lamoth et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungiCryptococcus gattiiandCryptococcus neoformans
- (2015) Luiz R. Basso et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Structural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2
- (2015) Huiseon Yang et al. Nature Communications
- Positions and Numbers ofFKSMutations in Candida albicans Selectively InfluenceIn VitroandIn VivoSusceptibilities to Echinocandin Treatment
- (2014) M. Lackner et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance
- (2014) Cau D. Pham et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans
- (2014) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ChIP-seq and In Vivo Transcriptome Analyses of the Aspergillus fumigatus SREBP SrbA Reveals a New Regulator of the Fungal Hypoxia Response and Virulence
- (2014) Dawoon Chung et al. PLoS Pathogens
- Population-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study)
- (2013) A. Alastruey-Izquierdo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Enfumafungin Derivative MK-3118 Shows IncreasedIn VitroPotency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates
- (2013) Cristina Jiménez-Ortigosa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Gain-of-Function Mutations inPDR1, a Regulator of Antifungal Drug Resistance in Candida glabrata, Control Adherence to Host Cells
- (2013) Luís Vale-Silva et al. INFECTION AND IMMUNITY
- In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods
- (2012) M. A. Pfaller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Identification of a Cryptococcus neoformans Cytochrome P450 Lanosterol 14α-Demethylase (Erg11) Residue Critical for Differential Susceptibility between Fluconazole/Voriconazole and Itraconazole/Posaconazole
- (2011) Edward Sionov et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Discovery of a Novel Class of Orally Active Antifungal β-1,3-d-Glucan Synthase Inhibitors
- (2011) Scott S. Walker et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods
- (2011) Michael A. Pfaller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis
- (2011) Katsura Hata et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
- (2011) Mamiko Miyazaki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis
- (2011) Nao-aki Watanabe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods
- (2011) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method
- (2011) Michael A. Pfaller et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods
- (2011) M. A. Pfaller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Contribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
- (2011) Sélène Ferrari et al. PLoS One
- Cryptococcus neoformans Overcomes Stress of Azole Drugs by Formation of Disomy in Specific Multiple Chromosomes
- (2010) Edward Sionov et al. PLoS Pathogens
- Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with Virulence
- (2009) E. Sionov et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Gene Overexpression/Suppression Analysis of Candidate Virulence Factors ofCandida albicans
- (2008) Yue Fu et al. EUKARYOTIC CELL
- Candida albicans Cell Wall Proteins
- (2008) W. L. Chaffin MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- A Sterol-Regulatory Element Binding Protein Is Required for Cell Polarity, Hypoxia Adaptation, Azole Drug Resistance, and Virulence in Aspergillus fumigatus
- (2008) Sven D. Willger et al. PLoS Pathogens
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started